SCHEMBL10171223

SCHEMBL10171223

CC(C)(C)c1ccc(Nc2nc(NC3C4C=CC(C4)C3C(N)=O)c3cc[nH]c3n2)cc1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 10/20 0.62
KDR P35968 9/20 0.46
AURKB Q96GD4 9/20 0.46
AURKA O14965 1/20 0.45
LCK P06239 1/20 0.45
PDGFRA P16234 1/20 0.45
FGFR2 P21802 1/20 0.45
WEE1 P30291 1/20 0.45
FLT3 P36888 1/20 0.45
SYK P43405 1/20 0.45
GSK3B P49841 1/20 0.45
PRKCE Q02156 1/20 0.45
LRRK2 Q5S007 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10172038 0.84 IRAK4 (0.63) IRAK4KDRAURKBLRRK2
SCHEMBL10172040 0.84 IRAK4 (0.67) IRAK4KDRAURKBAURKALCK
SCHEMBL10171531 0.83 IRAK4 (0.60) IRAK4KDRAURKBAURKALCK
SCHEMBL10171186 0.83 IRAK4 (0.69) IRAK4
SCHEMBL10171496 0.83 IRAK4 (0.60) IRAK4KDRAURKBAURKALCK
SCHEMBL10172034 0.83 IRAK4 (0.73) IRAK4KDRAURKB
SCHEMBL12112324 0.83 IRAK4 (0.57) IRAK4KDRAURKBAURKALCK
SCHEMBL10171243 0.83 IRAK4 (0.63) IRAK4KDRAURKB
SCHEMBL14484007 0.81 IRAK4 (0.57) IRAK4KDRAURKBAURKALCK
SCHEMBL14513338 0.81 IRAK4 (0.57) IRAK4KDRAURKBAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834568-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160024116-A1 Kinase Inhibitors And Their Uses MIDCAP FINANCIAL TRUST 2016-01-28 US disclosed
US-9096542-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20120015937-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-8053434-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2011-11-08 US disclosed
US-20100069369-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2010-03-18 US disclosed
US-7601713-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-7601713-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
WO-2007070872-A1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 US disclosed
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015937-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885KDR 580/4885AURKB 233/4885
US-20160024116-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885KDR 580/4885AURKB 233/4885
US-20100069369-A1 Kinase Inhibitors And Their Uses BTK, SYK, JAK2 IRAK4 293/4885KDR 560/4885AURKB 265/4885
US-20070142402-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885KDR 580/4885AURKB 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.